A feasibility study of combination with oral fluoropyrimidine, oxaliplatin and trastuzumab for HER2-positive advanced or recurrent gastric cancer
Not Applicable
- Conditions
- HER2-positive unresectable advanced gastric cancer
- Registration Number
- JPRN-UMIN000021554
- Lead Sponsor
- agoya University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1. HER2 negative 2. Uncontrolled diabetes 3. Uncontrolled hypertension 4. Unstable angina pectoris 5. Synchronous cancers 6. Systemic infection requiring treatment 7. Fever above 38 degree Celsius 8. A possibility of pregnancy or during pregnancy, or lactating women 9. Continuous systemic administration of steroids 10. Resistance to trastuzumab 11. Peripheral neuropathy Grade 2 or more 12. Oxaliplatin allergy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Adverse events
- Secondary Outcome Measures
Name Time Method Overall survival, progression-free survival, and response rate